pilocarpine hydrochloride · Abbvie · NDA 214028
Vuity
Earliest generic entry, as listed
24 Apr 2039
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 10610518, US 10610518, US 10610518, US 11285134, US 11285134, US 11285134. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10610518 | use U-3562 | 24 Apr 2039 |
| US 10610518 | use U-3561 | 24 Apr 2039 |
| US 10610518 | use U-3252 | 24 Apr 2039 |
| US 11285134 | use U-3561 | 24 Apr 2039 |
| US 11285134 | use U-3562 | 24 Apr 2039 |
| US 11285134 | use U-3252 | 24 Apr 2039 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214028 · 001 · RLD · discontinued | solution/drops, ophthalmic | 1.25% | 24 Apr 2039 |
Expired or delisted (1)
- D-187 · 28 Mar 2026